Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $342.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Option Exercise | $11.34 | 105,000 | $1,191,100 | 129,353 | Jul 22 04:05 PM |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Sale | $30.34 | 105,000 | $3,185,656 | 24,353 | Jul 22 04:05 PM |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 '26 | Option Exercise | $11.28 | 40,000 | $451,000 | 64,353 | Jun 24 04:10 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.